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HIV-associated sensory neuropathy (HIV-SN) is a 
common and frequently painful complication of HIV 
infection and its treatment, and is likely to remain 
prevalent for the foreseeable future.[1-3] Painful 
HIV-SN is associated with substantially reduced 
health-related quality of life,[2] but evidence-based analgesic options 
are lacking.[4] Several national and international agencies[5-10] have 
recommended the tricyclic antidepressant amitriptyline for HIV-SN 
pain, despite evidence that this is no better than placebo.[11,13]
Despite the high prevalence[1,2] and considerable impact of HIV-
SN, and the lack of proven effective analgesics, few data exist 
describing the frequency, type and dosage of pain medication patients 
are receiving. We are aware of only one retrospective case review, with 
low-quality case ascertainment criteria, that attempted to describe the 
treatment of HIV-SN pain in a clinical setting.[14] This showed that 
only 7% of a cohort of Malawians who may have had painful HIV-SN 
were prescribed amitriptyline.
We used validated case ascertainment criteria to identify patients 
with painful HIV-SN, and provide the first report on analgesic 
prescription for HIV-SN among South African (SA) adults on 
combination antiretroviral therapy (cART).
Methods
Consecutive consenting HIV-positive adults on cART were screened 
for HIV-SN at the Greenhouse Pharmacy, which services patients 
attending the Ntabiseng Clinic at Chris Hani Baragwanath Hospital, 
Johannesburg, SA, between June 2012 and January 2014. Researchers 
attended all pharmacy days servicing ambulatory adults infected with 
HIV. All individuals on stable cART (any regimen) for longer than 6 
months and who had HIV-SN (painful or non-painful) were included 
in the study. The study was approved by the Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand, 
Johannesburg. Informed consent was obtained from all participants.
Patients were screened for HIV-SN using the AIDS Clinical Trials 
Group (ACTG) Brief Neuropathy Screening Tool (BPNS).[15] HIV-SN 
was diagnosed on the basis of at least one bilateral sign (vibration sense 
<10 seconds using a 128 Hz tuning fork in the great toe or absent ankle 
reflexes) and at least one symptom (pain, paraesthesiae or numbness) 
in both feet. Symptom severity was rated on an 11-point numerical 
pain rating scale (NRS) ranging from 0 (not present) to 10 (most 
severe imaginable). Demographic and clinical data (including current 
prescribed and self-medicated analgesic use) were collected on direct 
questioning of the patient and review of the medical file.
Descriptive statistics are presented as means (standard deviation 
(SD)) for parametric data, medians (interquartile range (IQR)) for 
non-parametric data, and percentages for frequency data. Univariate 
analyses comparing patients receiving and not receiving analgesic 
therapy included Fisher’s exact test (gender, years of formal education, 
number of pain sites, ART regimen, current tuberculosis (TB) 
infection, sensory symptoms other than pain), the Wilcoxon rank sum 
test (pain intensity, CD4 T-cell count, years of formal education), and 
Student’s t-test (age). Variables with p<0.1 on univariate analysis were 
included in multivariate logistic regression analysis. For those patients 
who were receiving analgesic therapy, the Cochrane-Armitage test for 
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trend was used to assess whether there was 
an association between the dose of analgesic 
prescribed and pain intensity. Pain was 
categorised as mild if rated 1 - 3, moderate if 
rated 4 - 7, and severe if rated 8 - 10, as set out 
in the ACTG BPNS.[15]
Results
One hundred and thirty black SA patients with 
painful HIV-SN were recruited. Consistent with 
the population seen in clinics in Johannesburg,[16] 
the subjects were predominantly middle-aged 
women (72% female, mean (SD) age 45.7 (9.4) 
years) with well-preserved CD4 T-cell counts. 
Current HIV-SN pain was rated as severe 
by two-thirds of the subjects, with an overall 
median pain intensity of 7.5 (IQR 2 - 10) on the 
numerical rating scale. Details of the clinical and 
demographic features of the cohort are shown 
in Table 1.
Significant associations were observed 
between the use of analgesic medication and 
current pain severity (individuals with greater 
pain were more likely to be using analgesics: 
median difference in pain intensity rating on 
the 11-point NRS (95% CI of difference in 
medians) 4 (0 - 5)), and between the use 
of analgesic medication and the latest CD4 
T-cell count (individuals with lower CD4 T-cell 
counts were more likely to be using analgesics: 
median difference in CD4 T-cell count (95% 
CI of difference in medians) –138 (–315 - 
21) cells/µL). Multivariate logistic regression 
models incorporating combinations of pain 
intensity, CD4 T-cell count and number of 
pain sites (p<0.1 on univariate analysis) were 
not significantly better than a model only 
incorporating pain intensity as an independent 
variable (analysis of deviance p>0.05). CD4 
T-cell count was not associated with pain 
intensity (Spearman’s rho –0.08, p=0.35).
Pharmacological treatments prescribed to 
the patients are shown in Table 2. Overall, 64% 
of patients were using at least one analgesic 
medication, including three-quarters of those 
with severe pain, half of those with moderate 
pain and one-quarter of those who described 
their current pain as mild. Consistent with 
national guidelines, amitriptyline was the 
most commonly used agent, either alone or 
in combination therapy.
In patients receiving analgesic therapy, 
there was no association between drug 
dosage prescribed and pain intensity for 
amitriptyline (χ2=1.88, p=0.18), or for para-
cetamol and codeine (χ2=0.01, p=0.94).
During the patient interview, we also 
collected information on over-the-counter 
medications participants were taking. The 
majority of patients were only taking those 
medications provided at the pharmacy, as 
they could not afford to buy their own 
medications. Of the few patients who did so, 
none purchased pain medications.
Discussion
We provide the first report of analgesic use for 
HIV-SN pain in which HIV-SN was defined 
using standard, objective criteria. Ninety per 
cent of patients in our sample had moderate or 
severe pain, despite almost two-thirds being on 
some form of analgesic therapy. In most cases 
the tricyclic antidepressant amitriptyline was 
included in the analgesic regimen, consistent 
with national guidelines.[6,7] We found 
significant associations, of moderate size, 
between pain intensity and analgesic therapy as 
well as between CD4 T-cell count and analgesic 
Table 2. Pharmacological medications prescribed for patients with painful HIV-SN
Analgesic (mg) n (%) Median daily dose (mg) (min - max)*
Ami 25, monotherapy 23 (27.7) 25 (25 - 50)
Ami 25 + para 320 + cod 8 33 (39.8) Ami 25 (25 - 75)/para 2 560 (1 920 - 2 560)/cod 64 (48 - 64)
Ami 25 + ibu 200 3 (3.6) Ami 25 (25 - 25)/ibu 200 (200 - 200)
Ami 25 + para 320 + cod 8 
+ ibu 200
4 (4.8) Ami 37.5 (25 - 75)/para 2 560 (2 560 - 2 560)/cod 64 
(64 - 64)/ibu 200 (200 - 400)
Ami 25 + para 320 + cod 8 
+ carb 200
6 (7.2) Ami 25 (25 - 50)/para 2 240 (1 920 - 2 560)/cod 56 (48 
- 64)/carb 100 (100 - 200)
Para 320 + cod 8 only 14 (16.9) Para 1 920 (1 920 - 2 560)/cod 48 (48 - 64)
Ami = amitriptyline; para = paracetamol; cod = codeine; ibu = ibuprofen; carb = carbamazepine.
*Dose frequency was prescribed according to recommended dosing strategies for individual drugs in all cases.
Table 1. Demographic and clinical characteristics of the cohort and univariate 











Female gender, n (%) 93 (71.5) 57 (68.7) 36 (76.6) 0.42 
Age (years), mean (SD) 45.7 (9.4) 45.4 (9.3) 46.2 (9.8) 0.63 
CD4 T-cell count (cells/
µL), median (IQR)
409 (34 - 1 606) 369 (34 - 1 092) 507 (63 - 1 606) 0.04
Formal education (years), 
median (IQR)
6 (0 - 8) 6 (0 - 8) 6 (0 - 8) 0.94 
Current TB infection, n (%) 8 (6.2) 6 (7.2) 2 (4.3) 0.71
Treatment regimen, n (%) 0.26
TDF based 81 (62.3) 52 (62.7) 29 (61.7)
AZT based 25 (19.2) 17 (20.5) 8 (17.0)
D4T based 17 (13.1) 12 (14.5) 5 (10.6)
Other 7 (5.4) 2 (2.4) 5 (10.6)
Pain intensity, median (IQR) 7.5 (2 - 10) 10 (2 - 10) 6 (2 - 10) 0.01 
Pain intensity rating, n (%) <0.01*
Mild 12 (9.2) 3 (3.6) 9 (19.1)
Moderate 34 (26.2) 18 (21.7) 16 (34.0)
Severe 84 (64.6) 62 (74.7) 22 (46.8)
Number of pain sites, 
median (IQR)
3 (1 - 9) 3 (1 - 9) 3 (1 - 7) 0.06 
Prevalence of other 
symptoms, n (%)
Paraesthesiae 114 (87.7) 79 (95.2) 35 (74.5) 0.001
Numbness 116 (89.2) 77 (92.8) 39 (83.0) 0.13
TDF = tenofovir; AZT = zidovudine; D4T = stavudine.
*Post-hoc analysis identified a greater proportion of patients with severe pain in the group receiving analgesics.
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therapy; subjects with more severe pain and those with lower CD4 T-cell 
counts were more likely to be receiving treatment. However, greater pain 
was not associated with analgesic dose used, and lower CD4 T-cell counts 
were not associated with pain intensity. Factors previously identified as 
predicting analgesic treatment in HIV-positive individuals (age, gender, 
level of education) were not associated with analgesic use in this study.[17]
Our finding that 36% of patients with HIV-SN pain were not receiving 
any analgesic therapy is worrying. Nevertheless, analgesic use in this 
cohort was high compared with the very low rates we and others have 
reported in similar ambulatory HIV-positive populations with pain of 
similar intensity, but of any origin.[18-21] Clinicians may be more aware 
of HIV-SN as a common cause of pain, and therefore be more likely to 
recognise and treat HIV-SN pain than other pain conditions. Although 
more than a third of patients with HIV-SN pain in this cohort were not 
receiving analgesics, we cannot exclude the possibility that they may 
previously have used agents such as amitriptyline and ceased these owing 
to poor tolerability or efficacy. Indeed, the high levels of pain reported by 
many patients using amitriptyline in this cohort highlight the need for 
more effective treatments for HIV-SN pain,[12] or greater awareness of 
optimal dosing of amitriptyline for the management of neuropathic pain.
Our finding that use of some form of analgesic agent increases 
with pain severity may indicate that physicians believe that regular 
analgesics are required only for HIV-SN pain of greater severity, 
despite evidence that health-related quality of life is reduced across 
all levels of pain in this condition.[2] However, it is also possible 
that patients do not report mild pain. In addition, our finding 
that analgesic use increases with lower initial CD4 T-cell count 
may indicate that patients perceive sensory neuropathy to be a 
complication of ART, and more of those patients with severe pain and 
severe paraesthesiae (median 8, IQR 2 - 10) may therefore not take 
their ART reliably, possibly thinking that they are being harmed by 
these drugs, and therefore have a poor CD4 T-cell count.
Amitriptyline was prescribed to most patients receiving analgesia 
in this cohort. While there is no evidence that amitriptyline is more 
effective than placebo for painful HIV-SN,[11-13] its proven efficacy 
in other types of neuropathic pain[22] prompted an expert panel to 
recommend it as a first-line option for HIV-SN pain in SA.[7] These 
patients were therefore receiving a recommended treatment, albeit at a 
relatively low dose (25 - 50 mg/d).[7] Amitriptyline was commonly used 
in combination with codeine and paracetamol. Neither of these drugs 
have proven efficacy in neuropathic pain,[22] but their use may reflect 
concurrent sources of pain (common in HIV) that may be responsive 
to standard opioid and non-opioid analgesics and non-steroidal anti-
inflammatory agents.[23] Use only of agents with no evidence of efficacy 
for neuropathic pain by 16% of our cohort may reflect poor knowledge 
of neuropathic pain management on the part of clinicians, inadequate 
efficacy and/or tolerability of available neuropathic pain treatments, or 
treatment of concurrent nociceptive pains while the neuropathic pain 
went unrecognised. This finding highlights the need for both better 
analgesic options for HIV-SN pain treatment and ongoing training and 
support of clinicians managing this difficult condition.
Six patients (7%) were prescribed amitriptyline together with the 
anticonvulsant carbamazepine, largely owing to the preference of 
a single clinician. Carbamazepine decreases levels of amitriptyline 
and paracetamol by affecting hepatic/intestinal enzyme CYP3A4 
metabolism.[24] There is also potential for increased sedation in patients 
taking codeine and amitriptyline concurrently, but at the doses of 
codeine prescribed, this interaction was probably not significant.[25]
Study limitations
Our study has a number of limitations. The modest sample size limits 
our ability to understand factors associated with use of less common 
analgesic choices. The cross-sectional nature of this work means that 
we are unable to comment on patients’ previous level of HIV-SN pain 
or prior use of analgesics for this condition. We therefore cannot 
comment on the level of pain relief achieved by the treatments used. 
Patients also express preferences for analgesic therapy, with some not 
wanting certain analgesics because they fear side-effects, which may 
affect treatment choices. Moreover, we do not have data on comorbid 
diseases for which analgesics may have been prescribed, including 
depression (amitriptyline) and seizure disorders (carbamazepine), 
although we would have expected higher doses to have been used in 
these situations.[26,27]
Conclusion
We found that most patients with HIV-SN pain in a large SA HIV care 
clinic were receiving analgesics consistent with the recommendation 
in the national guidelines. However, about one in six patients were 
only receiving agents with no demonstrated efficacy for neuropathic 
pain. Furthermore, despite the observed high level of treatment 
coverage, the majority of patients described their current level of 
HIV-SN pain as moderate or severe, highlighting the urgent need for 
better therapies for this common and disabling condition.
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